MK-2866 (Ostarine) 20mg is a selective androgen receptor modulator (SARM) oral compound supplied in a 50 tablet pack. Manufactured for consistent potency, stability, and research applications.
Format50 Tablets
Concentration20mg
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
MK-2866, commonly known as Ostarine or Enobosarm, is the most extensively clinically studied SARM in current research literature having progressed through multiple Phase II clinical trials examining cancer related muscle wasting and cachexia, and currently advancing through Phase III trials for indications including stress urinary incontinence and ER+ breast cancer, contributing the largest human clinical dataset of any SARM compound. F40 Biotech’s formulation delivers 20mg per tablet in a 50 count format, consistent with the upper end of the dose range most frequently referenced in Ostarine clinical trial literature.
Ostarine’s clinical development history distinguishes it meaningfully from LGD-4033, S23, and YK-11 within CSD’s SARM range. While all share the broad non steroidal tissue selective androgen receptor activation principle, Ostarine’s clinical trials have generated documented data on lean body mass increases in elderly and cachectic patient populations with comparatively favorable tolerability findings relative to other SARM compounds at clinically studied doses. A research distinction that has made it the most frequently referenced reference compound in comparative SARM tolerability and efficacy research. Its relatively mild HPG axis suppression profile at lower research doses compared to higher affinity compounds like S23 has additionally generated specific interest in dose response studies examining the relationship between androgen receptor binding affinity and the magnitude of endogenous testosterone suppression across the SARM compound class.
Ostarine’s mechanism follows the same non steroidal androgen receptor binding principle shared across true SARMs, avoiding 5-alpha reductase and aromatase enzyme interaction while activating downstream anabolic signaling preferentially in muscle and bone tissue. Its pharmacokinetic profile includes a half-life of approximately 24 hours, supporting once daily research administration consistent with the dosing schedules referenced in its clinical trial protocols. This combination of extensive clinical documentation and comparatively well characterized tolerability has positioned Ostarine as the most frequently used reference compound in academic and industry sponsored comparative SARM research.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s MK-2866 meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside LGD-4033 and S23 in comparative SARM clinical trial data and receptor binding affinity studies. Browse CSD’s full SARM range for complete sourcing.
Ostarine (MK-2866) is the most extensively clinically researched SARM available, originally developed by GTx Inc. and subsequently researched by Merck under the name Enobosarm. It has completed multiple Phase II clinical trials for muscle wasting in cancer patients and osteoporosis research, demonstrating meaningful lean mass preservation and bone density improvements at doses of 1–3mg daily in clinical research. In performance research contexts, Ostarine is studied at higher doses of 10–25mg daily for lean mass preservation, recomposition, injury recovery, and mild anabolic effects with minimal androgenic activity, minimal HPG axis suppression at conservative doses and cycle lengths, and no aromatization to estrogen.
The 20mg tablet dose covers the most commonly researched performance dose range for Ostarine. 20mg daily is the single most studied dose in performance research contexts, demonstrating meaningful lean mass and strength improvements with manageable suppression at standard 6–8 week cycle lengths. A single 20mg tablet once daily is the simplest and most practical Ostarine research administration schedule given its 24 hour half-life. The 50 tablet pack at 20mg provides 1000mg total; sufficient for a complete 50 day research cycle at once daily 20mg dosing, covering an 8 week protocol with buffer.
Yes! Ostarine is the most commonly recommended starting point for SARM research due to its extensive clinical data, mild suppression profile at standard doses, absence of androgenic side effects, no aromatization, and the most comprehensive human safety data of any SARM. Its forgiving pharmacological profile. Meaningful anabolic effects at conservative doses with manageable side effects, makes it the most appropriate compound for researchers new to SARM protocols, researchers returning from injury, or researchers seeking mild anabolic support during caloric deficit without the suppression burden of more potent SARMs.
Ostarine produces mild, dose dependent HPG axis suppression, significantly less than LGD-4033, RAD-140, or S23 at equivalent doses. At 20mg daily for 6–8 weeks, most research subjects experience mild testosterone suppression that recovers naturally within 4–6 weeks post cycle without formal SERM intervention. However blood work before and after the research cycle is strongly recommended to assess individual suppression response. Researchers experiencing significant suppression or running longer cycles at higher doses may benefit from a mild 2–4 week Nolvadex PCT at 20mg daily to accelerate HPG axis recovery.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming concentration accuracy at 20mg per tablet and compound identity as Ostarine (MK-2866). A certificate of analysis is available.
